根据治疗前风险分层评估吡格列酮或磺脲类的心血管效应:迈向个体化治疗
本研究基于TOSCA.IT试验2820例2型糖尿病参与者,用RECPAM方法按治疗前心血管风险分为四个亚组,评估吡格列酮或磺脲类对复合终点(全因死亡、非致死性心肌梗死、非致死性卒中、紧急冠脉血运重建)的长期效应。结果显示,在男性且尿白蛋白/肌酐比值>9 mg/g、BMI>28.7 kg/m2的高风险组中,吡格列酮较磺脲类显著降低终点事件(HR 0.48,95%CI 0.25-0.76),其他亚组无显著差异。
要点
- RECPAM识别出男性、UACR>9 mg/g且BMI>28.7 kg/m2为最高风险组(HR 5.58)。
- 该高风险组中吡格列酮较磺脲类显著降低复合终点(HR 0.48)。
- 其他RECPAM亚组中两种治疗无显著差异。
核心结论
- 在TOSCA.IT试验中,对于男性、UACR>9 mg/g且BMI>28.7 kg/m2的2型糖尿病高风险患者,吡格列酮较磺脲类显著降低复合心血管终点事件。
研究设计与样本
- 基于TOSCA.IT试验2820例2型糖尿病参与者的二次分析,采用RECPAM方法按治疗前心血管风险分为四个亚组,评估吡格列酮或磺脲类对复合终点的效应。
主要发现
- RECPAM首先按性别拆分,其次按UACR(>9 mg/g或≤9 mg/g)和BMI(>28.7或≤28.7 kg/m2)拆分。
- 女性患者风险最低(参照),男性且UACR>9 mg/g、BMI>28.7 kg/m2者风险最高(HR 5.58,95%CI 3.32-9.69)。
- 该高风险组具有明显胰岛素抵抗特征(更高BMI、腰围、甘油三酯、血压和UACR,更低高密度脂蛋白胆固醇)。
- 该高风险组中吡格列酮较磺脲类显著降低复合终点(HR 0.48,95%CI 0.25-0.76)。
- 其他RECPAM亚组中两种治疗无显著差异。
关键数值与推荐
- 复合终点包括全因死亡、非致死性心肌梗死、非致死性卒中、紧急冠脉血运重建。
- 高风险组吡格列酮对比磺脲类的HR为0.48(95%CI 0.25-0.76)。
- 最高风险组(男性、UACR>9 mg/g、BMI>28.7 kg/m2)对比女性参照的HR为5.58(95%CI 3.32-9.69)。
临床怎么用
- 对于2型糖尿病早期、无明显心血管疾病但具有胰岛素抵抗特征(男性、UACR>9 mg/g、BMI>28.7 kg/m2)的患者,在二甲双胍基础上加用吡格列酮可能较磺脲类提供心血管保护。
- 其他风险亚组中吡格列酮与磺脲类的心血管效应无显著差异,选择治疗时需综合考虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Hypoglycemic drugs with proven cardiovascular (CV) benefits are recommended for patients with type 2 diabetes and CV disease. Whether the beneficial effects extend to those at lower risk remains unclear. AIM: We investigated the long-term CV effects of pioglitazone or sulfonylureas (SUs) across the spectrum of pretreatment CV risk. METHODS: Among 2820 participants of the TOSCA.IT trial, four subgroups with different risk of outcome-a composite of all-cause death, nonfatal myocardial infarction, nonfatal stroke, urgent coronary revascularization-were identified by the RECursive Partitioning and AMalgamation (RECPAM) method. Within each group, the effect of SUs or pioglitazone on the outcome was evaluated. RESULTS: Sex was the first splitting variable, followed by urinary albumin-to-creatinine ratio (UACR) (>9 mg/g or ≤9 mg/g) and body mass index (BMI) (>28.7 or ≤28.7 kg/m2). Female patients had the lowest risk (reference); male patients with UACR >9 mg/g and BMI >28.7 kg/m2 had the highest risk [hazard ratio (HR), 5.58; 95% CI, 3.32 to 9.69]. Patients in this group present a cluster of conditions suggestive of marked insulin resistance (higher BMI, waist circumference, triglycerides, blood pressure, and UACR and lower high-density lipoprotein cholesterol) than the other groups. Treatment with pioglitazone in this group was associated with a significantly lower occurrence of the outcome than SUs (HR, 0.48; 95% CI, 0.25 to 0.76). No significant difference between study treatments was observed in the other RECPAM classes. CONCLUSIONS: It is possible to identify patients with type 2 diabetes early in the stage of their disease and who are largely free from evident CV disease in whom add-on pioglitazone to metformin confers CV protection as compared with SUs.
引用
- Vaccaro O, Lucisano G, Masulli M, et al. Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care. J Clin Endocrinol Metab. 2019. PMID: 31058962. doi:10.1210/jc.2019-00361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。